The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates
Science Translational Medicine · 30.08.2023 · 15 (711)
DOI: 10.1126/scitranslmed.adf6376 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 30.08.2023. Verfasst von Imran J Anwar und 14 weiteren Autor:innen. Beteiligte Einrichtung: Duke Transplant Center, Department of Surgery, Duke University School of Medicine; Durham, NC 27710, USA. Hauptthemen laut MEDLINE: Kidney, Antibodies, Monoclonal. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Prior studies of anti-CD40 ligand (CD40L)–based immunosuppression demonstrated effective prevention of islet and kidney allograft rejection in nonhuman primate models; however, clinical development was halted because of thromboembolic complications. An anti-CD40L-specific monoclonal antibody, AT-1501 (Tegoprubart), was engineered to minimize risk of thromboembolic complications by reducing binding to Fcγ receptors expressed on platelets while preserving binding to CD40L. AT-1501 was tested in both a cynomolgus macaque model of intrahepatic islet allotransplantation and a rhesus macaque model of kidney allotransplantation. AT-1501 monotherapy led to long-term graft survival in both islet and kidney transplant models, confirming its immunosuppressive potential. Furthermore, AT-1501–based regimens after islet transplant resulted in higher C-peptide, greater appetite leading to weight gain, and reduced occurrence of cytomegalovirus reactivation compared with conventional immunosuppression. These data support AT-1501 as a safe and effective agent to promote both islet and kidney allograft survival and function in nonhuman primate models, warranting further testing in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Duke Transplant Center, Department of Surgery, Duke University School of Medicine; Durham, NC 27710, USA.
- Diabetes Research Institute, University of Miami, Miami, FL 33136, USA.
- Department of Surgery, University of Miami, Miami, FL 33136, USA.
- ALS Therapy Development Institute, Cambridge, MA 02472, USA.
- Eledon Pharmaceuticals, Irving, CA 92612, USA.
- Department of Microbiology and Immunology, University of Miami, Miami, FL 33136, USA.
ORCID-Profile: Imran J Anwar, Dora M Berman, Isabel DeLaura, Qimeng Gao, Melissa A Willman, Allison Miller, Alan Gill, Cindy Gill, Philip Ruiz, Mingqing Song, Joseph M Ladowski, Allan D Kirk, Norma S Kenyon
Förderung
- NIAID NIH HHS
Zitieren
APA
Anwar, I. J., Berman, D. M., DeLaura, I., Gao, Q., Willman, M. A., Miller, A., Gill, A., Gill, C., Perrin, S., Ricordi, C., Ruiz, P., Song, M., Ladowski, J. M., Kirk, A. D., & Kenyon, N. S. (2023). The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates. Science Translational Medicine, 15(711). https://doi.org/10.1126/scitranslmed.adf6376
Vancouver
Anwar IJ, Berman DM, DeLaura I, Gao Q, Willman MA, Miller A, et al. The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates. Science Translational Medicine. 2023;15(711). doi:10.1126/scitranslmed.adf6376
BibTeX
@article{Anwar2023,
author = {Anwar, Imran J and Berman, Dora M and DeLaura, Isabel and Gao, Qimeng and Willman, Melissa A and Miller, Allison and Gill, Alan and Gill, Cindy and Perrin, Steve and Ricordi, Camillo and Ruiz, Philip and Song, Mingqing and Ladowski, Joseph M and Kirk, Allan D and Kenyon, Norma S},
title = {The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates},
journal = {Science Translational Medicine},
year = {2023},
volume = {15},
number = {711},
doi = {10.1126/scitranslmed.adf6376}
}
EUVIMED